NIOX Group PLC (NIOX) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.130x

Based on the latest financial reports, NIOX Group PLC (NIOX) has a cash flow conversion efficiency ratio of 0.130x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX8.80 Million ≈ $1.07K USD) by net assets (GBX67.60 Million ≈ $8.22K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

NIOX Group PLC - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how NIOX Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of NIOX Group PLC for a breakdown of total debt and financial obligations.

NIOX Group PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NIOX Group PLC ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Poddar Housing and Development Limited
NSE:PODDARHOUS
0.838x
Hochdorf Holding AG
SW:HOCN
-0.550x
Zaplox AB
ST:ZAPLOX
25.961x
Century Global Commodities Corp
TO:CNT
-0.047x
Techfast Holdings Bhd
KLSE:0084
-0.008x
NuGen Medical Devices Inc
V:NGMD
0.122x
Superior Mining International Corp
V:SUI
0.002x
Group 107 Ltd
TA:G107
-0.133x

Annual Cash Flow Conversion Efficiency for NIOX Group PLC (2013–2025)

The table below shows the annual cash flow conversion efficiency of NIOX Group PLC from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see NIOX Group PLC market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 GBX67.60 Million
≈ $8.22K
GBX15.80 Million
≈ $1.92K
0.234x -19.15%
2024-12-31 GBX59.50 Million
≈ $7.24K
GBX17.20 Million
≈ $2.09K
0.289x +108.83%
2023-12-31 GBX83.80 Million
≈ $10.20K
GBX11.60 Million
≈ $1.41K
0.138x 0.00%
2023-12-30 GBX83.80 Million
≈ $10.20K
GBX11.60 Million
≈ $1.41K
0.138x +69.21%
2022-12-31 GBX81.90 Million
≈ $9.96K
GBX6.70 Million
≈ $815.20
0.082x 0.00%
2022-12-30 GBX81.90 Million
≈ $9.96K
GBX6.70 Million
≈ $815.20
0.082x +290.34%
2021-12-31 GBX66.80 Million
≈ $8.13K
GBX1.40 Million
≈ $170.34
0.021x 0.00%
2021-12-30 GBX66.80 Million
≈ $8.13K
GBX1.40 Million
≈ $170.34
0.021x +105.80%
2020-12-31 GBX66.10 Million
≈ $8.04K
GBX-23.90 Million
≈ $-2.91K
-0.362x 0.00%
2020-12-30 GBX66.10 Million
≈ $8.04K
GBX-23.90 Million
≈ $-2.91K
-0.362x -22.16%
2019-12-31 GBX84.80 Million
≈ $10.32K
GBX-25.10 Million
≈ $-3.05K
-0.296x 0.00%
2019-12-30 GBX84.80 Million
≈ $10.32K
GBX-25.10 Million
≈ $-3.05K
-0.296x -33.41%
2018-12-31 GBX183.00 Million
≈ $22.27K
GBX-40.60 Million
≈ $-4.94K
-0.222x 0.00%
2018-12-30 GBX183.00 Million
≈ $22.27K
GBX-40.60 Million
≈ $-4.94K
-0.222x -43.13%
2017-12-31 GBX371.60 Million
≈ $45.21K
GBX-57.60 Million
≈ $-7.01K
-0.155x 0.00%
2017-12-30 GBX371.60 Million
≈ $45.21K
GBX-57.60 Million
≈ $-7.01K
-0.155x +14.54%
2016-12-31 GBX312.60 Million
≈ $38.03K
GBX-56.70 Million
≈ $-6.90K
-0.181x 0.00%
2016-12-30 GBX312.60 Million
≈ $38.03K
GBX-56.70 Million
≈ $-6.90K
-0.181x -43.32%
2015-12-31 GBX440.90 Million
≈ $53.64K
GBX-55.80 Million
≈ $-6.79K
-0.127x 0.00%
2015-12-30 GBX440.90 Million
≈ $53.64K
GBX-55.80 Million
≈ $-6.79K
-0.127x +34.56%
2014-12-31 GBX190.80 Million
≈ $23.21K
GBX-36.90 Million
≈ $-4.49K
-0.193x 0.00%
2014-12-30 GBX190.80 Million
≈ $23.21K
GBX-36.90 Million
≈ $-4.49K
-0.193x +67.50%
2013-12-31 GBX30.05 Million
≈ $3.66K
GBX-17.88 Million
≈ $-2.18K
-0.595x 0.00%
2013-12-30 GBX30.05 Million
≈ $3.66K
GBX-17.88 Million
≈ $-2.18K
-0.595x --

About NIOX Group PLC

LSE:NIOX UK Medical Devices
Market Cap
$3.41 Million
GBX28.01 Billion GBX
Market Cap Rank
#29012 Global
#552 in UK
Share Price
GBX67.00
Change (1 day)
-1.47%
52-Week Range
GBX54.40 - GBX76.00
All Time High
GBX306.79
About

NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled N… Read more